InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,221.42
(
-0.02%
)
US TECH 100
17,732.80
(
0.05%
)
Dow Jones
39,431.51
(
-0.21%
)
Brent Oil
83.16
(
-0.07%
)
Bitcoin
61,833.91
(
-1.70%
)
Post# of 15274
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

powderbum

Send PM Follow Ignore
Followers 11
Posts 2159
Boards Moderated 0
Alias Born 04/22/2009

powderbum

Re: None

Thursday, 09/22/2016 9:05:39 AM

Thursday, September 22, 2016 9:05:39 AM

Post# of 15274
Something to keep an eye on: We own this technology.

Palatin Technologies

Palatin Technologies Inc. (NYSEMKT: PTN) has completed its last patient visits for its late-stage reconnect studies, which consist of two pivotal Phase 3 clinical trials of bremelanotide for the treatment of female hypoactive sexual desire disorder. Management noted that patient enrollment and last patient out of the studies were concluded on time. It is now looking forward to data verification and database lock, which it anticipates will occur in late September. The top-line results should follow shortly after, which is expected to be in October.

Shares of Palatin were last seen at $0.51, within a 52-week range of $0.36 to $0.94. The consensus price target is $4.00.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up